Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biophytis S.A. stock logo
BPTS
Biophytis
$13.37
$8.05
$168.80
$2.89M1.057,291 shs18,500 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.39
+14.4%
$0.75
$0.25
$4.71
$5.49M1.381.94 million shs3.60 million shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.57
-1.9%
$1.36
$0.95
$5.99
$17.76M1.4380,166 shs76,501 shs
Rallybio Corporation stock logo
RLYB
Rallybio
$0.34
+2.3%
$0.33
$0.22
$1.54
$14.16M-1.17128,190 shs56,447 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biophytis S.A. stock logo
BPTS
Biophytis
0.00%0.00%0.00%0.00%0.00%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
0.00%+12.11%-47.76%-55.59%-89.97%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%+7.95%-10.96%+56.04%-68.29%
Rallybio Corporation stock logo
RLYB
Rallybio
0.00%+1.62%-14.43%-20.45%-74.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biophytis S.A. stock logo
BPTS
Biophytis
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.1483 of 5 stars
3.52.00.00.03.41.71.3
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.2093 of 5 stars
3.83.00.03.90.00.80.6
Rallybio Corporation stock logo
RLYB
Rallybio
2.1483 of 5 stars
3.03.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biophytis S.A. stock logo
BPTS
Biophytis
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.00928.81% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.17738.64% Upside
Rallybio Corporation stock logo
RLYB
Rallybio
2.00
Hold$10.002,837.72% Upside

Current Analyst Ratings Breakdown

Latest BPTS, RLYB, MRKR, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
4/15/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/13/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/9/2025
Rallybio Corporation stock logo
RLYB
Rallybio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
4/8/2025
Rallybio Corporation stock logo
RLYB
Rallybio
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biophytis S.A. stock logo
BPTS
Biophytis
N/AN/AN/AN/A($17.29) per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M2.69N/AN/A$1.73 per share0.91
Rallybio Corporation stock logo
RLYB
Rallybio
$640K22.13N/AN/A$1.49 per share0.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biophytis S.A. stock logo
BPTS
Biophytis
-$18.43MN/A0.00N/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)
Rallybio Corporation stock logo
RLYB
Rallybio
-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/14/2025 (Estimated)

Latest BPTS, RLYB, MRKR, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
5/8/2025Q1 2025
Rallybio Corporation stock logo
RLYB
Rallybio
-$0.21-$0.21N/A-$0.21N/A$0.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biophytis S.A. stock logo
BPTS
Biophytis
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biophytis S.A. stock logo
BPTS
Biophytis
N/A
0.72
0.72
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.79
6.79
Rallybio Corporation stock logo
RLYB
Rallybio
N/A
14.68
14.68

Institutional Ownership

CompanyInstitutional Ownership
Biophytis S.A. stock logo
BPTS
Biophytis
0.05%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Rallybio Corporation stock logo
RLYB
Rallybio
90.34%

Insider Ownership

CompanyInsider Ownership
Biophytis S.A. stock logo
BPTS
Biophytis
3.70%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1.90%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
14.50%
Rallybio Corporation stock logo
RLYB
Rallybio
8.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biophytis S.A. stock logo
BPTS
Biophytis
22351,000338,000Not Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.86 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.31 million9.67 millionNot Optionable
Rallybio Corporation stock logo
RLYB
Rallybio
4041.61 million37.99 millionNot Optionable

Recent News About These Companies

Jones Trading Downgrades Rallybio (RLYB)
Rallybio downgraded to Hold from Buy at JonesResearch
Rallybio downgraded to In Line from Outperform at Evercore ISI
Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright
Rallybio discontinues RLYB212 program
Rallybio sinks as it drops RLYB212 for prevention of FNAIT
Citizens JMP downgrades Rallybio on RLYB212 discontinuation
JMP Securities downgrades Rallybio (RLYB) to a Hold
Rallybio reports Q4 EPS (25c), consensus (30c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biophytis stock logo

Biophytis NASDAQ:BPTS

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.39 +0.05 (+14.35%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 +0.02 (+4.42%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.57 -0.03 (-1.88%)
As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.34 +0.01 (+2.31%)
As of 04:00 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.